TLDR: Fangzhou Inc., a leading provider of AI-driven Internet healthcare solutions, was honored with the ‘Social Responsibility Golden Bull Award’ at the 2025 Xiamen Industry Development Conference. This award recognizes their pioneering efforts and leadership in leveraging artificial intelligence for chronic disease management, aligning with China’s national health priorities.
Fangzhou Inc. (HKEX: 06086), a prominent provider of AI-driven Internet healthcare solutions, has been honored with the ‘Social Responsibility Golden Bull Award’ at the 2025 Xiamen Industry Development Conference and Listed Companies (Hong Kong) Golden Bull Awards Ceremony. The event, organized by China Securities Journal, celebrated Hong Kong-listed enterprises demonstrating innovation and strong governance for sustainable global growth. This year marked the inaugural edition of the Golden Bull Awards for Hong Kong-listed companies.
Fangzhou distinguished itself among its peers, showcasing not only robust revenue growth and solid profitability but also leadership in technological innovation and sustained social value creation. The award specifically underscores the growing confidence in the company’s ‘AI + chronic disease management’ strategy, a field identified as high-growth and high-impact that is actively reshaping China’s digital healthcare landscape.
Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou, expressed gratitude, stating, ‘We are honored to receive the award and will continue to advance AI-driven chronic disease management and deliver lasting benefits for public health.’
This recognition aligns with recent policy guidance from China’s National Health Commission, which has promoted the application of ‘AI + Healthcare’ as a key national development priority. In response, Fangzhou has developed an AI + H2H (Hospital-to-Home) ecosystem. This system integrates its proprietary XJ LLM and XS LLM to enhance the precision, efficiency, and accessibility of chronic disease management.
As of June 30, 2025, Fangzhou Inc. serves 52.8 million registered users and collaborates with 229,000 physicians, specializing in tailored medical care and AI-enabled precision medicine solutions. The company also recently established the ‘AI + Hepatitis Prevention and Control Training Center’ in April of this year, in collaboration with the Guangdong Provincial Institute of Liver Disease.
Also Read:
- China’s Business Sector Embraces Generative AI: Rapid Growth and Diverse Applications
- Global Leaders Urge AI Collaboration and Ethical Standards at Beijing Forum
The Golden Bull Awards, established by China Securities Journal and approved by national authorities, are renowned for their rigorous and transparent evaluation system, making them one of China’s most authoritative platforms for fostering positive interaction between industry and capital markets.
